Citations

Clear

3138 citation(s) found for "Smith, AM".

Three-dimensional microscale hanging drop arrays with geometric control for drug screening and live tissue imaging
Ganguli, Anurup , Mostafa, Ariana , Saavedra, Carlos , Kim, Yongdeok , Le, Phuong , Faramarzi, Vahid , Feathers, Ryan W. , Berger, Jacob , Ramos-Cruz, Karla P. , Adeniba, Olaoluwa O. , Diaz, Gustavo, Drnevich, Jenny , Wright, Chris , Hernandez, Alvaro G. , Lin, Wen-Wei , Smith, Andrew M. , Kosari, Farhad , Vasmatzis, George , Anastasiadis, Panos Z. , Ganguli, A , Mostafa, A , Le, P , Faramarzi, V , Ramos-Cruz, K P , Drnevich, J , Wright, Christy L , Hernandez, Alvaro G , Smith, A M , Anastasiadis, P Z , Bashir, R , Saavedra, C., Bashir, Rashid

Mayo Clinic

Science Advances | April 23, 2021 | Volume: 7 | Issue: 17 | Pages: No page available

10.1126/sciadv.abc1323 | PMID 33893093 Get It

Tiny silicon microchip–based high-throughput hanging drop arrays allow drug screening and geometric control.
Assessment of Cumulative Incidence and Severity of Primary Open-Angle Glaucoma Among Participants in the Ocular Hypertension Treatment Study After 20 Years of Follow-up
Heuer, Dale K. , Higginbotham, Eve J. , Parrish, Richard , Khanna, Cheryl L. , Brandt, James D. , Soltau, Joern B., Keltner, John L., Huecker, Julia B., Wilson, Bradley , Gordon, Mae O. , Group, Ocular Hypertension Study, Gedee, Steven J., Esquiabro, Maria, Fabrizio, Matthew J., Patorgis, Charles J., Long, Teresa A., McManus, Paul E., Washington, Chantura, Chang, Peter , Orengo-Nania, Silvia, Leger, April, Kinast, Robert M. , Jones, Emily P., Goldman, Casie, Beck, Allen D. , Costarides, Anastasios P., Leef, Donna, Imami, Nauman R., Darnley-Fisch, Deborah , Crandall, David, Gutkowski, Melanie, Hall, Julianne, Fantin, Aldo, Wells, Judy, Jampel, Henry , Quigley, Harry A., Miller, Rhonda, Kalarn, Sachin , Coleman, Anne L. , Young, Jonathan W., Peterson, Christine A., Giaconi, JoAnn A. , Law, Simon K., Duarte, Pamela B., Wood, Sarah Dougherty , Moroi, Sayoki, Gilbert, Jesse L., Shukairy, Aman, Juzych, Mark S. , Milanovic, Cheryl, O'Grady, John M., Conett, Linda A. Van, Mohay-Ambrus, Judith, Bottorff, Michelle, Bennett, Jeffrey R., Sultze, Jane L., Patel, Dharmendra, Cobb, Steven H., Bhattacharjee, Pompa, Cioffi, George A., Blumberg, Dana M., Moraes, Carlos Gustavo De , Atakulova, Marzhan, Weber, Paul A., Sawchyn, Andrea K., Williams, Demarcus, Bennett, George, Bennett, Lindsay C., Miller-Ellis, Eydie , Sankar, Prithvi S. , Grand-Drossner, Sheri, Piltz‐Seymour, Jody R., Niemczyk, Jane L., Brandt, James D., Lim, Michelle, Balasubramaniam, Saranya C., Baik, Annie K., Arnold, Marisa S., Slight, J. Rigby, Ou, Yvonne , Lamping, Kathleen A., Vitelli, Cheryl L., Ashburn, Frank S., Hardney, Karen S., Schwartz, Arthur L., Weiss, Howard S., Clark, Clete, Bhorade, Anjali M., Lind, John T., Adcock, Eve, Plumb, Kim, Leming, Laura, Dillon, B A, Palmberg, Paul, Hodapp, Elizabeth, Varner, Elizabeth A., Savatovsky, Eleonore , Vandenbroucke, Ruth, Dirkes, Keri , Vega, Suzanne , Hunsicker, Maria, Proudfoot, J. , Dunn, D, Everett, Donald F., Gutowski, Melanie, Fischbach, Ellen, Clark, Karen A., Morris, Patricia A., Quinn, Melanie, Pistorius, Sam, Haertter, Leonard W., Kass, Michael A. , Johnson, Chris A. , Liu, Lei , Miller, J. Philip , Quigley, Harry A. , Group, Ocular Hypertension Study, Patorgis, Charles J., Washington, Chantura, Mansberger, Steven L. , Wells, Judy, Quigley, Harry A., Saeedi, Osamah J. , Hughes, Bret A. , Liebmann, Jeffrey M. , Al‐Aswad, Lama A. , Brandt, James D., Lim, Michelle C., Weinreb, Robert Neal , Smith, Mike A., Feuer, William J. , Zangwill, Linda M. , Morris, Patricia A.

Mayo Clinic

JAMA Ophthalmology | April 17, 2021 | Volume: 139 | Issue: 5 | Pages: 558

10.1001/jamaophthalmol.2021.0341 | PMID 33856434 Get It

Imaging of the Primary Visual Pathway based on Visual Deficits
Patel, Swapnil C., Kessler, Alex , Bhatt, Alok A. , Bhatt, Alok A , Smith, Stephen M.

Mayo Clinic

Journal of Clinical Imaging Science | April 7, 2021 | Volume: 11 | Issue: No issue available | Pages: 19

10.25259/jcis_12_2021 | PMID 33880244 Get It

Vision loss can occur due to a variety of etiologies along the primary visual pathway. Understanding the anatomic organization of the visual pathway, which spans the globe to the occipital cortex, can help tailor neuroimaging to identify the cause of visual dysfunction. In this review, relevant anatomy and optimization of computed tomography and magnetic resonance imaging techniques will be described. This will be followed by a discussion of imaging findings related to pathologies at each functional anatomic level.
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer
Shafique, Michael , Fisher, Terrence L. , Evans, Elizabeth E. , Leonard, John E. , Pastore, Desa Rae E. , Mallow, Crystal, Smith, Ernest, Mishra, Vikas , Schröder, Andreas , Chin, Kevin M. , Baumgart, Megan , Govindan, Ramaswamy , Gabrail, Nashat , Lou, Yanyan , Zauderer, Maurice , Shafique, Michael R , Beck, Joseph T , Baumgart, Megan A , Seetharamu, Nagashree , Mansfield, Aaron S , Sanborn, Rachel E , Goldman, Jonathan W , Govindan, Ramaswamy , Beck, J. Thaddeus , Spira, Alexander I. , Mansfield, Aaron S. , Goldman, Jonathan W.

Mayo Clinic

Clinical Cancer Research | April 5, 2021 | Volume: 27 | Issue: 13 | Pages: 3630-3640

10.1158/1078-0432.ccr-20-4792 | PMID 33820783 Get It

Abstract Purpose: The CLASSICAL-Lung clinical trial tested the combination of pepinemab, an IgG4 humanized mAb targeting semaphorin 4D, with the PD-L1 inhibitor avelumab to assess the effects of coupling increased T-cell infiltration and reversal of immune suppression via pepinemab with sustained T-cell activation via checkpoint inhibition. Patients and Methods: This phase Ib/II, single-arm study was designed to evaluate the safety, tolerability, and efficacy of pepinemab in combination with avelumab in 62 patients with advanced non–small cell lung cancer (NSCLC), including immunotherapy-naïve (ION) patients and patients whose tumors progressed following anti-PD-1/L1 monotherapy (IOF). The main objectives were to evaluate safety/tolerability, establish a recommended phase 2 dose (RP2D), obtain a preliminary evaluation of antitumor activity, and investigate candidate biomarker activity. Results: The combination was well tolerated with no major safety signals identified. Pepinemab, 10 mg/kg with avelumab, 10 mg/kg, every 2 weeks, was selected as the RP2D. Among 21 evaluable ION patients, 5 patients experienced partial responses (PR), 4 patients evidenced clinical benefit ≥1 year, and the disease control rate (DCR) was 81%. Notably, overall response rate with the combination therapy was higher than previously reported for single-agent avelumab in the PD-L1-negative/low population. Among 29 evaluable IOF patients, the combination resulted in a DCR of 59%, including 2 PR and 7 patients with durable clinical benefit of ≥23 weeks. Biomarker analysis of biopsies demonstrated increased CD8 T-cell density correlating with RECIST response criteria. Conclusions: The combination of pepinemab with avelumab was well tolerated in NSCLC and showed signs of antitumor activity in immunotherapy-resistant and PD-L1-negative/low tumors.
Automated identification of glomeruli and synchronised review of special stains in renal biopsies by machine learning and slide registration: a cross‐institutional study
Wilbur, David C. , Cornell, Lynn D. , Andryushkin, Alexander, Pettus, Jason R. , Cornell, Lynn , Smith, Maxwell L.

Mayo Clinic

Histopathology | April 4, 2021 | Volume: 79 | Issue: 4 | Pages: 499-508

10.1111/his.14376 | PMID 33813779 Get It

AimsMachine learning in digital pathology can improve efficiency and accuracy via prescreening with automated feature identification. Studies using uniform histological material have shown promise. Generalised application requires validation on slides from multiple institutions. We used machine learning to identify glomeruli on renal biopsies and compared performance between single and multiple institutions.Methods and resultsRandomly selected, adequately sampled renal core biopsy cases (71) consisting of four stains each (haematoxylin and eosin, trichrome, silver, periodic acid Schiff) from three institutions were digitised at ×40. Glomeruli were manually annotated by three renal pathologists using a digital tool. Cases were divided into training/validation (n = 52) and evaluation (n = 19) cohorts. An algorithm was trained to develop three convolutional neural network (CNN) models which tested case cohorts intra‐ and inter‐institutionally. Raw CNN search data from each of the four slides per case were merged into composite regions of interest containing putative glomeruli. The sensitivity and modified specificity of glomerulus detection (versus annotated truth) were calculated for each model/cohort. Intra‐institutional (3) sensitivity ranged from 90 to 93%, with modified specificity from 86 to 98%. Interinstitutional (1) sensitivity was 77%, with modified specificity 97%. Combined intra‐ and inter‐institutional (1) sensitivity was 86%, with modified specificity 92%.ConclusionsFeature detection sensitivity degrades when training and test material originate from different sites. Training using a combined set of digital slides from three institutions improves performance. Differing histology methods probably account for algorithm performance contrasts. Our data highlight the need for diverse training sets for the development of generalisable machine learning histology algorithms.
Association Between Antifibrinolytic Therapy and Perioperative Outcomes in Patients With Coronary Artery Stents Undergoing Noncardiac Surgery
Boswell, Michael R. , Frank, Ryan D. , Brown, Michael J., Abcejo, Arnoley S., Kor, Todd M. , Gulati, Rajiv , Boswell, Michael R., Smith, Mark M. , Smith, Bradford B.

Mayo Clinic

Anesthesia & Analgesia | March 29, 2021 | Volume: 132 | Issue: 6 | Pages: 1635-1644

10.1213/ane.0000000000005522 | PMID 33780399 Get It

BACKGROUND: Patients with existing coronary artery stents are at an increased risk for major adverse cardiac events (MACEs) when undergoing noncardiac surgery (NCS). Although the use of antifibrinolytic (AF) therapy in NCS has significantly increased in the past decade, the relationship between perioperative AF use and its association with MACEs among patients with existing coronary artery stents has yet to be assessed. In this study, we aim to evaluate the association of MACEs in patients with existing coronary artery stents who receive perioperative AF therapy during orthopedic surgery. METHODS: A single-center retrospective cohort study was conducted in adult patients with existing coronary artery stents who underwent orthopedic surgery from 2008 to 2018. Two cohorts were established: patients with existing coronary artery stents who did not receive perioperative AF and patients with coronary artery stents who received perioperative AF. Associations between AF use and the primary outcome of MACEs within 30 days postoperatively and the secondary outcomes of thrombotic complications, excessive surgical bleeding, and intensive care unit (ICU) admissions were analyzed using logistic regression models. Inverse probability of treatment weighting was used to control for confounding. Secondary analyses examining the association between coronary stent type/timing and the outcomes of interest were performed using unadjusted logistic regression models. RESULTS: A total of 473 patients met study criteria, including 294 who did not receive AF and 179 patients who received AF. MACEs occurred in 15 (5.1%) patients who did not receive AF and 1 (0.6%) who received AF ( P = .007). In weighted analyses, no significant difference was found in patients who received AF with regard to MACEs (odds ratio [OR] = 0.13, 95% confidence interval [CI], 0.01-1.74, P = .12), thrombotic complications (OR = 1.19, 95% CI, 0.53-2.68, P = .68), or excessive surgical bleeding (OR = 0.13, 95% CI, 0.01-2.23, P = .16) compared to patients who did not receive AF. CONCLUSIONS: The results of this study are inconclusive whether an association exists between perioperative AF use in patients with coronary artery stents and the outcome of MACEs compared to patients who did not receive perioperative AF therapy. The authors acknowledge that the imprecise CI hinders the ability to definitively determine whether an association exists in the study population. Further large prospective studies, powered to detect differences in MACEs, are needed to assess the safety of perioperative AF in patients with existing coronary artery stents and to clarify the mechanism of perioperative MACEs in this high-risk population.
Hierarchical Bayesian clustering design of multiple biomarker subgroups (HCOMBS)
Kang, Daniel , Coffey, Christopher S. , Smith, Brian J, Yuan, Ying , Shi, Qian , Yin, Jun , Shi, Qian , Smith, Brian J

Mayo Clinic

Statistics in Medicine | March 27, 2021 | Volume: 40 | Issue: 12 | Pages: 2893-2921

10.1002/sim.8946 | PMID 33772843 Get It

Given the Food and Drug Administration's (FDA's) acceptance of master protocol designs in recent guidance documents, the oncology field is rapidly moving to address the paradigm shift to molecular subtype focused studies. Identifying new “marker‐based” treatments requires new methodologies to address the growing demand to conduct clinical trials in smaller molecular subpopulations, identify effective treatment and marker interactions, and control for false positives. We introduce our methodology, Hierarchical Bayesian Clustering Design of Multiple Biomarker Subgroups (HCOMBS), a two‐stage umbrella Phase II design with effect size clustering and information borrowing across multiple biomarker‐treatment pairs. HCOMBS was designed to reduce required sample size, differentiate between varying effect sizes, and control for operating characteristics in the multi‐arm setting. When compared to independently applied Simon's Optimal two‐stage design, we showed through simulations that HCOMBS required less participants per treatment arm with a well‐controlled family‐wise error rate and desirable marginal power. Additionally, HCOMBS features a statistical approach that simultaneously conducts clustering and hypothesis testing in one step. We also applied the proposed design on the alliance brain metastases umbrella trial.
Musicogenic epilepsy: Expanding the spectrum of glutamic acid decarboxylase 65 neurological autoimmunity
Smith, Kelsey M. , Zalewski, Nicholas L. , So, Elson, Cascino, Gregory D. , Ritaccio, Anthony L. , Pittock, Sean J. , Dubey, Divyanshu , Budhram, Adrian , Pittock, S J , Dubey, Divyanshu , Smith, Kelsey M , Britton, Jeffrey W. , So, Elson L., McKeon, Andrew

Mayo Clinic

Epilepsia | March 25, 2021 | Volume: 62 | Issue: 5 | Pages: No page available

10.1111/epi.16888 | PMID 33764529 Get It

AbstractThe objective of this study was to describe serological association of musicogenic epilepsy and to evaluate clinical features and outcomes of seropositive cases. Through retrospective chart review, musicogenic epilepsy patients were identified. Among 16 musicogenic epilepsy patients, nine underwent autoantibody evaluations and all had high‐titer glutamic acid decarboxylase 65–immunoglobulin G (GAD65‐IgG; >20 nmol·L–1, serum, normal ≤ .02 nmol·L–1, eight women). Median GAD65‐IgG serum titer was 294 nmol·L–1 (20.3–3005 nmol·L–1), and median cerebrospinal fluid titer (n = 4) was 14.7 nmol·L–1. All patients had temporal lobe epilepsy, and bitemporal epileptiform abnormalities were common. Right temporal lobe seizures were most frequently captured when seizures were induced by music on electroencephalogram (3/4; 75%). Intravenous (IV) methylprednisolone and/or IV Ig (IVIG) was utilized in four patients, with one having greater than 50% reduction. Rituximab (n = 2) and mycophenolate (n = 1) were ineffective. Two patients underwent right temporal lobe resections but continued to have seizures. Vagus nerve stimulation was effective at reducing seizures in one patient by 50%, and an additional patient was seizure‐free by avoiding provoking music. Right temporal lobe epilepsy was more common among patients with musicogenic epilepsy when compared to nonmusicogenic GAD65 epilepsies (n = 71, 89% vs. 47%, p = .03). GAD65‐IgG should be tested in patients with musicogenic epilepsy, given implications for management and screening for comorbid autoimmune conditions.